Clinical trial NCT01941030: Complete Lesion Assessment With ffR and IVUS TechnologY
Official title: Complete Lesion Assessment With ffR and IVUS TechnologY (CLARITY I)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Artery Disease
Critical Limb Ischemia
Keywords: Peripheral Artery Disease
Critical Limb Ischemia
Orbital Atherectomy
Balloon Angioplasty
Intravascular Ultrasound (IVUS)
Fractional Flow Reserve (FFR)
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2013-09-13
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: CLARITY I is a pilot study to identify the clinically appropriate endpoint(s) of a larger, statistically powered pivotal trial for treatment of patients with Critical Limb Ischemia (CLI).

Detailed description: This prospective, randomized, multi-center, post-market study of approximately 50 subjects randomized 1:1 to Orbital Atherectomy (OA) performed with Cardiovascular Systems, Inc.'s Orbital Atherectomy System (OAS) followed by adjunctive balloon angioplasty (BA) vs. BA alone for treatment of tibial vessel disease, defined as ≥ 50 % stenosis of the anterior tibial (AT), posterior tibial (PT), tibial peroneal trunk (TPT), or peroneal (PR) arteries by angiography. All subjects will have a corresponding wound being fed by the target vessel which will be assessed during the study. Subjects will be followed to one year.

Eligibility criteria: General Inclusion Criteria:

1. Subject's age ≥ 18 years.
2. Subject is an acceptable candidate for percutaneous intervention with the Sponsor's OAS and BA in accordance with their labeled indications and instructions for use.
3. Subject is willing and able to sign an approved informed consent form (ICF).
4. Subject is willing and able to attend follow-up and wound care visits.

General Exclusion Criteria:

1. Subject is pregnant or planning to become pregnant within the study period.
2. Subject is currently participating in an investigational drug or other device study that can clinically interfere with the endpoints of this trial.
3. Subject has a known sensitivity to contrast media and the sensitivity cannot be adequately pre-medicated.
4. Uncontrolled allergy to nitinol, stainless steel, or other stent materials.
5. Subject has known allergy to atherectomy lubricant components such as soybean oil, egg yolk phospholipids, glycerin or sodium hydroxide.
6. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
7. Subject has been diagnosed with chronic renal failure or has a creatinine level \> 2.5, unless on dialysis, prior to the index treatment.
8. Subject has evidence of intracranial or gastrointestinal bleeding within 90 days.
9. Subject has a history of trauma, fracture, major surgery (includes major amputation), or biopsy of a parenchymal organ within past 14 days, or patient has not healed from a previous medical intervention occurring more than 14 days.
10. Subject has a history of stroke or myocardial infarction (MI) within 90 days prior to enrollment in the study.
11. Subject has a planned major surgery (includes major amputation) scheduled within 60 days after treatment of the index limb.
12. Subject has a planned interventional treatment to address stenosis of the contralateral limb scheduled within 60 days after the index treatment.
13. Subject has a planned interventional treatment to address inflow stenosis of the ipsilateral limb scheduled within 60 days after the index treatment.
14. Inflow or bilateral PAD requiring treatment prior to enrollment was not successfully treated, defined as \> 50% residual stenosis and/or occurrence of procedural angiographic complications, excluding dissection types A and B.
15. Subject has previously had their other limb treated as part of the study.

Angiographic Inclusion Criteria:

1. Target lesion(s) located in the anterior tibial (AT), posterior tibial (PT), tibial peroneal trunk (TPT) or peroneal (PR) arteries.
2. Target lesion has ≥ 50 % stenosis by angiography.
3. Subject has a corresponding wound being fed by the target vessel.

Angiographic Exclusion Criteria:

1. Target limb does not have any visual flow to the foot confirmed via distal selective angiography.
2. Thrombus is present or suspected in the target treatment vessel.
3. Target lesion is within a bypass graft or near a previously placed stent.
4. The guide wire cannot be passed across the target lesion.
5. Anterograde access of the lesion is not possible.
6. Subject has angiographic evidence of significant dissection at or near the treatment site.
7. Interventional treatment is intended for in-stent restenosis at the peripheral vascular site.
8. Subject's wound(s) involve multiple angiosomes.

Primary outcomes:
measure: Percentage of Calcium Removal Out of Lumen Gain as Assessed by IVUS
timeFrame: Post-balloon angioplasty
measure: Change in Minimum Lumen Area Percent Stenosis as Assessed by IVUS
timeFrame: Pre-intervention, and post-balloon angioplasty
measure: Change in Plaque Area as Assessed by IVUS
timeFrame: Pre-intervention, and post-balloon angioplasty
measure: Change in Dense Calcium Area as Assessed by IVUS
timeFrame: Pre-intervention, and post-balloon angioplasty
measure: Change in Necrotic Core Area as Assessed by IVUS
timeFrame: Pre-intervention, and post-balloon angioplasty
measure: Change in Fibrous Plaque Area as Assessed by IVUS
timeFrame: Pre-intervention, and post-balloon angioplasty
measure: Change in Fibrofatty Plaque Area as Assessed by IVUS
timeFrame: Pre-intervention, and post-balloon angioplasty
Secondary outcomes:
measure: Fractional Flow Reserve
timeFrame: Post-orbital atherectomy (OA arm only) and post-balloon angioplasty (both arms)
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Heart Clinic
state: Arkansas
city: Atlanta
country: United States
facility: Northside Hospital
state: Georgia
city: Davenport
country: United States
facility: Midwest Cardiovascular Research Foundation
state: Iowa
city: Detroit
country: United States
facility: St. John Hospital and Medical Center
state: Michigan
city: Teaneck
country: United States
facility: Holy Name Medical Center
state: New Jersey
city: Raleigh
country: United States
facility: Rex Hospital
state: North Carolina
city: New Braunfels
country: United States
facility: Mission Research Institute
state: Texas
city: Norfolk
country: United States
facility: Sentara Vascular Specialists
state: Virginia
Study officials:
affiliation: St. Francis Heart and Vascular Center
name: Raymond Dattilo, M.D.
role: PRINCIPAL_INVESTIGATOR
References: